viral
infect
heart
rel
common
usual
littl
consequ
howev
lead
substanti
cardiac
damag
sever
acut
heart
failur
also
evolv
progress
syndrom
chronic
heart
failur
recent
studi
gone
way
toward
unravel
complex
mechan
underli
heart
muscl
damag
occur
viral
infect
studi
lent
support
immun
viral
mediat
independ
immun
respons
cardiac
damag
acut
myocard
present
variou
way
may
caus
sudden
death
otherwis
healthi
young
adult
new
treatment
viral
heart
diseas
await
meanwhil
haemodynam
support
patient
acut
left
ventricular
failur
caus
myocard
aggress
allow
possibl
spontan
recoveri
contemporari
trial
treatment
chronic
heart
failur
secondari
dilat
cardiomyopathi
support
use
angiotensin
convert
enzym
inhibitor
adrenoceptor
blocker
spironolacton
patient
postgrad
med
j
despit
signific
progress
prevent
treatment
cardiovascular
diseas
incid
preval
chronic
heart
failur
continu
rise
whatev
underli
aetiolog
sever
heart
failur
mortal
within
one
year
diagnosi
unit
kingdom
evalu
care
patient
chronic
heart
failur
take
account
lost
wage
product
estim
cost
nh
million
day
myocard
common
caus
dilat
cardiomyopathi
western
world
underli
aetiolog
patient
undergo
heart
transplant
relat
infect
chronic
heart
diseas
suggest
earli
corvisart
describ
cardiac
inflammatori
disord
could
result
progress
abnorm
cardiac
function
evid
infect
agent
disappear
myocard
initi
sever
diver
infect
agent
includ
virus
parasit
protozoa
fungi
viral
infect
thought
common
caus
myocard
review
focu
viral
myocard
progress
dilat
cardiomyopathi
current
treatment
dilat
cardiomyopathi
virus
known
caus
myocard
list
box
hiv
import
caus
heart
muscl
diseas
full
review
beyond
scope
articl
review
see
barbaro
coxsacki
b
viru
often
associ
myocard
member
picornaviru
famili
enteroviru
genu
close
relat
enterovirus
echoviru
polioviru
rhinoviru
adult
time
infect
cardiotrop
viru
seri
healthi
adult
neutralis
antibodi
two
serotyp
coxsacki
b
detect
sera
test
applic
cellular
molecular
biolog
approach
investig
mechan
viral
myocardi
damag
understand
myocard
progress
dilat
cardiomyopathi
increas
substanti
clear
understand
pathophysiolog
progress
heart
muscl
damag
develop
dilat
cardiomyopathi
import
manag
often
fluctuat
diseas
like
immun
mediat
direct
viral
cytotox
mechan
myocar
immunocompet
patient
immun
respons
stimul
viral
protein
limit
viral
replic
major
patient
clear
viru
host
howev
immun
respons
caus
damag
myocardium
balanc
benefici
detriment
evect
respons
significantli
influenc
extent
cardiac
cell
loss
viral
invas
myocardium
first
wave
infiltr
immun
cell
consist
natur
killer
nk
cell
nk
cell
thought
cardioprotect
evect
limit
viru
replic
evid
murin
model
myocard
mice
defici
nk
cell
respons
sever
myocard
nk
cell
infiltr
accompani
product
variou
cytokin
includ
interleukin
il
tumour
necrosi
factor
tnf
interferon
cytokin
may
benefici
deleteri
evect
myocardi
function
review
see
matsumori
experiment
studi
report
benefici
evect
surviv
subsequ
myocardi
function
murin
model
myocard
convinc
data
show
detriment
evect
tnf
myocard
also
recent
data
show
vasoconstrictor
substanc
endothelin
play
role
pathogenesi
myocard
time
first
wave
nk
cell
also
nklike
cell
unlik
nk
cell
caus
myocardi
damag
releas
perforin
molecul
form
circular
porelik
lesion
membran
surfac
cardiac
myocyt
contribut
myocardi
cytoskelet
disrupt
second
wave
cell
seen
myocardium
lymphocyt
peak
day
viru
inocul
coincid
sever
phase
myocardi
damag
cell
thought
play
import
role
viral
clearanc
immun
mediat
cardiac
damag
cell
shown
capabl
destroy
viru
infect
cardiocyt
vitro
propos
cell
may
injur
viral
infect
myocyt
molecular
mimicrythat
myocardi
antigen
bear
similar
viral
protein
caus
lymphocyt
origin
aim
viru
cross
react
host
antigen
produc
myocyt
damag
product
cardiac
cell
destruct
may
stimul
cell
lysi
cell
balanc
benefici
detriment
evect
immun
respons
human
less
clear
larg
trial
immunosuppress
treatment
patient
myocard
fail
show
benefici
evect
patient
receiv
immunosuppres
howev
smaller
trial
benefici
evect
give
immun
globulin
patient
myocard
recent
studi
shed
light
dichotomi
review
see
knowlton
bardorv
coxsacki
b
viru
infect
knockout
mice
lack
diver
compon
cellular
immun
system
opavski
et
al
show
activ
diver
cell
subtyp
import
determin
myocardi
damag
demonstr
absenc
lymphocyt
markedli
reduc
cellular
inflamm
mortal
caus
coxsacki
b
infect
henc
select
treatment
target
subset
immun
cell
may
evect
intervent
acut
viral
heart
diseas
time
treatment
also
like
import
determin
eycaci
much
interest
recent
role
nitric
oxid
synthas
no
acut
myocard
healthi
heart
nitric
oxid
deriv
endotheli
cell
modul
myocardi
relax
diastol
function
frankstarl
respons
improv
energet
eycienc
nitric
oxid
may
also
influenc
excitationcontract
coupl
heart
rate
adrenoceptor
respons
acut
myocard
signific
express
induc
isoform
no
ino
infiltr
inflammatori
cell
cardiac
myocyt
gener
larg
amount
nitric
oxid
radic
peroxynitrit
ino
express
probabl
induc
cytokin
tnf
ino
deriv
nitric
oxid
may
benefici
evect
antivir
activ
hand
excess
nitric
oxid
product
especi
context
increas
oxid
stress
may
detrimentalfor
exampl
caus
myocardi
depress
apoptosi
necrosi
balanc
benefici
detriment
evect
like
depend
spatial
tempor
pattern
ino
express
cours
diseas
direct
evect
viru
mediat
toxic
includ
focal
necrosi
myocyt
absenc
inflammatori
cell
infiltr
within
three
day
infect
time
nk
cell
protect
antivir
antibodi
infiltr
macrophag
begin
clear
viru
myocardium
without
aid
cytokin
despit
defenc
mechan
acut
viral
replic
maydepend
circumst
patientcaus
rapid
sever
cardiac
decompens
experiment
model
myocard
virul
cardiotrop
virus
increas
malnutrit
age
exercis
studi
anim
forc
perform
regular
physic
exercis
follow
infect
cardiotrop
viru
show
increas
cardiac
necrosi
mortal
sex
hormon
statu
also
contribut
outcom
viral
infect
heart
pregnanc
particularli
potent
predispos
factor
viral
myocard
dilat
cardiomyopathi
import
factor
though
immun
statu
initi
immun
respons
inevect
viru
elimin
chronic
myocard
evolv
potenti
develop
dilat
cardiomyopathi
mechan
involv
transit
viral
myocard
dilat
cardiomyopathi
diycult
elucid
recent
controversi
whether
presenc
enterovir
genom
heart
signific
aetiolog
chronic
diseas
whether
simpli
repres
remnant
previou
infect
two
studi
came
opposit
conclus
figulla
et
al
suggest
presenc
enterovir
rna
endomyocardi
biopsi
posit
prognost
factor
respect
haemodynam
clinic
outcom
prospect
studi
institut
show
presenc
enterovir
rna
myocardium
patient
myocard
dilat
cardiomyopathi
independ
predictor
advers
prognosi
persist
enterovir
adenovir
genom
identifi
polymeras
chain
reaction
pcr
situ
hybridis
heart
recent
studi
pausching
et
al
show
patient
left
ventricular
dysfunct
clinic
suspect
myocard
activ
enterovir
rna
replic
myocardium
studi
revers
transcriptas
pcr
use
detect
minu
strand
rna
transcript
minu
strand
rna
plu
strand
enterovir
templat
essenti
first
step
enterovir
replic
indic
activ
rna
replic
enterovir
genom
key
question
whether
replic
could
produc
new
antigen
noninfect
viral
protein
suycient
caus
ongo
myocardi
injuri
eleg
vitro
experi
wess
et
al
explor
evect
low
level
restrict
replic
enterovir
genom
isol
cardiac
myocyt
pattern
similar
observ
heart
persist
viral
infect
presenc
viral
genet
materi
enough
induc
cardiac
filament
disrupt
featur
myocardi
injuri
independ
host
cell
immun
evect
similar
experi
group
produc
persuas
data
support
role
enterovir
proteas
mediat
disrupt
cardiac
cell
cytoskeleton
recognis
featur
dilat
cardiomyopathi
subsequ
group
show
transgen
mice
cardiac
specif
express
full
length
copi
coxsacki
b
viru
genom
develop
morpholog
chang
abnorm
excitationcontract
coupl
similar
observ
dilat
cardiomyopathi
heart
mice
molecular
histolog
function
featur
resembl
human
dilat
cardiomyopathi
increas
left
ventricular
end
diastol
systol
dimens
reduc
left
ventricular
fraction
shorten
histolog
examin
reveal
myocyt
fibrosi
degener
studi
lend
convinc
support
hypothesi
low
level
express
viral
genomein
absenc
matur
infecti
viru
progenycan
induc
chronic
dynam
myocardi
injuri
clinic
characterist
patient
activ
myocard
summaris
box
major
patient
myocard
remain
asymptomat
cardiac
sequela
often
subclin
self
limit
howev
myocard
occasion
devast
ill
evolv
chronic
progress
diseas
clinic
manifest
variabl
reflect
abnorm
left
ventricular
systol
diastol
function
electr
activ
lead
arrhythmia
conduct
defect
mason
et
al
carri
largest
prospect
studi
patient
myocard
evalu
seri
patient
dilat
heart
histolog
evid
myocard
left
ventricular
eject
fraction
less
produc
import
clinic
data
natur
histori
myocard
show
mortal
taken
death
need
heart
transplant
one
year
four
year
earlier
studi
data
group
show
six
month
index
episod
acut
myocard
patient
develop
dilat
cardiomyopathi
left
ventricular
function
improv
normal
prognosi
good
wherea
residu
left
ventricular
impair
associ
poor
outcom
mason
et
al
found
patient
myocard
anteced
flulik
symptom
interest
studi
reflect
findingsin
seri
patient
influenza
suycient
sever
warrant
seen
doctorshow
ecg
abnorm
present
patient
chest
pain
also
common
manifest
myocard
patient
present
clinic
syndrom
mimick
acut
myocardi
infarct
chest
pain
left
ventricular
dysfunct
ecg
evid
myocardi
injuri
subsequ
necropsi
examin
usual
show
normal
coronari
arteri
anoth
uncommon
featur
myocard
system
pulmonari
thromboemboli
mechan
disturb
coagul
pathway
unclear
patient
myocard
ventricular
thrombu
detect
transthorac
echocardiographi
electr
sequela
myocard
may
becom
manifest
syncop
palpit
sudden
death
tachyarrhythmia
see
illustr
case
studi
box
heart
block
box
clinic
characterist
patient
activ
myocard
age
year
mean
sd
sex
male
flulik
symptom
chest
pain
rais
white
cell
count
increas
erythrocyt
sediment
rate
fever
seri
subject
age
sudden
unexpect
death
myocard
account
death
age
mason
et
al
also
evalu
evect
immunosuppress
treatment
cyclosporin
prednisolon
left
ventricular
function
mortal
patient
group
trial
show
featur
consist
stronger
immun
respons
associ
less
sever
initi
diseas
support
view
patient
myocard
promin
immunolog
respons
may
benefici
rather
detriment
howev
caveat
conclus
trial
involv
earli
immunosuppress
agent
use
may
necessarili
target
appropri
point
immun
respons
patient
suspect
myocard
blood
taken
erythrocyt
sediment
rate
c
reactiv
protein
determin
rais
white
blood
cell
count
rais
rais
titr
antibodi
enteroviru
may
present
simpli
denot
infect
time
fourfold
rise
igg
titr
four
week
period
necessari
establish
acut
infect
signific
risk
hiv
test
carri
involv
microbiologist
virologist
advis
patient
rise
creatin
kinas
may
provid
support
incorrect
diagnosi
acut
myocardi
infarct
electrocardiographi
electrocardiograph
abnorm
common
acut
myocard
box
divus
wave
abnorm
frequent
featur
lead
ecg
patient
develop
left
bundl
branch
block
complet
heart
block
also
common
usual
transient
rare
requir
implant
perman
pacemak
supraventricular
arrhythmia
common
patient
myobox
electrocardiograph
find
patient
myocard
sinu
tachycardia
divus
stt
wave
abnorm
prolong
qt
interv
bundl
branch
block
lbbb
found
myocardi
infarct
pattern
complet
heart
block
supraventricular
tachyarrhythmia
ventricular
tachyarrhythmia
year
old
west
african
man
admit
unconsci
intens
care
unit
hospit
cardiac
arrest
resuscit
friend
littl
medic
histori
note
recent
upper
respiratori
tract
infect
risk
factor
hiv
infect
intens
care
recurr
episod
ventricular
fibril
requir
multipl
dc
shock
ultim
settl
treatment
intraven
lignocain
lidocain
amiodaron
overdr
pace
rest
ecg
show
nonspecif
wave
chang
fig
intermitt
nonsustain
episod
broad
complex
irregular
tachycardia
fig
full
blood
count
urea
electrolyt
liver
function
test
normal
transthorac
echocardiographi
show
normal
left
ventricular
function
size
gradual
recov
without
sequela
electrophysiolog
test
reveal
induc
nonsustain
polymorph
ventricular
tachycardia
coronari
angiographi
entir
normal
right
ventricular
biopsi
taken
subsequ
show
heal
myocard
fig
patient
declin
implant
cardioverterdefibril
discharg
oral
amiodaron
carditi
ventricular
arrhythmia
infrequ
see
illustr
case
report
box
echocardiographi
echocardiographi
may
help
diagnost
left
ventricular
systol
dysfunct
often
seen
patient
acut
myocard
may
segment
reflect
frequent
focal
natur
myocardit
process
mimic
pattern
seen
region
ischaem
damag
left
ventricular
dimens
usual
increas
acut
phase
myocard
discuss
left
ventricular
thrombi
often
seen
characterist
trabecul
pattern
ventricular
wall
thicken
may
sometim
found
earli
diseas
process
inflamm
substanti
though
uncommon
first
describ
almost
year
ago
diagnosi
myocard
could
unequivoc
establish
antemortem
introduct
endomyocardi
biopsi
techniqu
pioneer
unit
kingdom
richardson
king
colleg
hospit
london
earli
accord
dalla
criteria
biopsi
evid
activ
myocard
show
inflammatori
infiltr
myocardium
without
degener
adjac
myocyt
typic
ischaem
damag
associ
coronari
arteri
diseas
survivor
acut
viral
myocard
histolog
featur
heal
progress
idiopath
dilat
cardiomyopathi
fig
carri
experienc
hand
left
right
ventricular
biopsi
techniqu
safe
biopsi
data
necessarili
alter
manag
establish
clear
diagnosi
thu
provid
detail
prognost
inform
evid
current
support
routin
use
immunosuppress
agent
acut
myocard
human
data
support
potenti
role
administr
immun
globulin
patient
new
onset
dilat
cardiomyopathi
secondari
myocard
preliminari
data
small
seri
patient
show
improv
eject
fraction
improv
function
new
york
heart
associ
class
iiiv
iii
data
preliminari
doubl
blind
outcom
trial
await
current
manag
patient
myocard
ensu
left
ventricular
dysfunct
follow
convent
line
patient
present
acut
heart
failur
secondari
myocard
treat
way
one
would
treat
patient
present
heart
failur
secondari
ischaem
heart
diseas
myocardi
insult
set
close
haemodynam
monitor
avail
pulmonari
oedema
treat
intraven
loop
diuret
nitrat
diamorphin
aggress
approach
manag
cardiogen
shock
adopt
function
recoveri
may
occur
despit
substanti
abnorm
left
ventricular
function
thu
intraven
inotrop
mechan
ventricular
support
exampl
intraaort
balloon
pump
use
necessari
allow
adequ
time
myocardi
recoveri
tachyarrhythmia
also
manag
convent
fashion
exercis
caution
use
antiarrhythm
agent
neg
inotrop
properti
patient
stabilis
residu
left
ventricular
systol
dysfunct
appropri
convent
treatment
given
use
ace
inhibitor
unequivoc
improv
prognosi
patient
heart
failur
caus
also
persuas
data
larg
trial
show
adrenoceptor
blocker
spironolacton
improv
outcom
heart
failur
ad
ace
inhibitor
trial
evalu
heart
failur
ischaem
nonischaem
cardiomyopathi
instanc
merithf
trial
larg
trial
adrenoceptor
blocker
metoprolol
includ
patient
nonischaem
dilat
cardiomyopathi
patient
recruit
similarli
rale
studi
trial
spironolacton
sever
heart
failur
patient
studi
nonischaem
dilat
cardiomyopathi
potenti
gradual
recoveri
left
ventricular
function
viru
induc
dilat
cardiomyopathi
may
possibl
reduc
even
discontinu
agent
clinic
echocardiograph
evid
complet
recoveri
treatment
myocard
summaris
box
cardiac
involv
viral
ill
common
may
often
go
unnot
howev
substanti
acut
haemodynam
clinic
sequela
may
lead
dilat
cardiomyopathi
heart
failur
recent
studi
identifi
key
role
persist
replic
viral
protein
within
myocardium
immun
mediat
cardiac
damag
occasion
progress
natur
diseas
possibl
role
induc
nitric
oxid
synthas
remain
clarifi
pathophysiolog
studi
may
ultim
provid
new
start
point
treatment
occasion
fatal
diseas
meantim
aggress
approach
acut
decompens
acut
myocard
use
ace
inhibitor
adrenoceptor
blocker
spironolacton
treatment
chronic
dilat
cardiomyopathi
form
optim
treatment
